Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Data Analytics for Biotech Firms: How EvoLV's Expertise Drives Innovation

Feb 18, 2025

Unlocking the Power of Data in Biotech

In today's rapidly evolving biotech landscape, data analytics has become a cornerstone for driving innovation and maintaining a competitive edge. By harnessing the power of data, biotech firms can make informed decisions that enhance research and development, streamline operations, and improve patient outcomes. At the forefront of this revolution is EvoLV, a leader in the field of data analytics, providing cutting-edge solutions tailored specifically for the biotech industry.

data analytics biotech

The Role of EvoLV in Biotech Innovation

EvoLV's expertise lies in transforming complex datasets into actionable insights. With a team of skilled data scientists and industry experts, EvoLV leverages advanced analytical tools to help biotech companies decipher intricate biological data. This not only accelerates the pace of research but also opens new avenues for drug discovery and personalized medicine.

By integrating artificial intelligence and machine learning into their analytics framework, EvoLV enables biotech firms to predict outcomes with greater accuracy. This predictive capability is crucial for anticipating market trends, optimizing supply chains, and enhancing clinical trial designs, ultimately leading to more efficient and effective product development.

Key Benefits of EvoLV's Data Analytics Solutions

Biotech companies partnering with EvoLV can expect a myriad of benefits that drive innovation and growth:

  • Enhanced Research and Development: By providing deeper insights into genomic and proteomic data, EvoLV facilitates the discovery of novel therapeutic targets.
  • Improved Efficiency: Streamlined processes and automated workflows reduce time and resource expenditure.
  • Regulatory Compliance: Comprehensive data management ensures adherence to industry standards and regulations.
biotech research

Real-World Applications

EvoLV's data analytics solutions have been instrumental in several real-world applications. For instance, their analysis of patient data has led to breakthroughs in personalized treatment plans for chronic diseases. Additionally, their work in optimizing clinical trials has reduced costs and accelerated time-to-market for new therapies.

Moreover, EvoLV's expertise in big data analytics allows for better understanding of patient populations, leading to improved strategies for patient recruitment and retention in clinical studies. This holistic approach ensures that biotech firms are not only innovating but also delivering tangible benefits to patients worldwide.

The Future of Biotech with EvoLV

As the biotech industry continues to grow, the importance of data analytics will only increase. EvoLV is committed to staying at the cutting edge of technology, continually refining their tools and methodologies to meet the ever-changing needs of their clients. Their dedication to innovation ensures that biotech companies can navigate future challenges with confidence.

The integration of EvoLV's data analytics solutions into biotech operations represents a significant step forward in leveraging data for strategic advantage. By enabling more informed decision-making, these solutions not only foster innovation but also contribute to the overall advancement of healthcare.

future technology

Conclusion

The partnership between EvoLV and biotech firms signifies a transformative era where data-driven strategies are pivotal in propelling innovation. As both industries continue to evolve, the synergy between biotech expertise and advanced analytics will unlock unprecedented opportunities for growth and discovery. With EvoLV at the helm, biotech firms are well-positioned to lead the charge towards a brighter, healthier future.